Timber Pharmaceuticals, Inc. (TMBR)
$0.3426
Rating:
Recommendation:
-
| Symbol | TMBR |
|---|---|
| Price | $0.3426 |
| Beta | -0.654 |
| Volume Avg. | 0.11M |
| Market Cap | 1.176M |
| Shares () | - |
| 52 Week Range | 0.32-3.39 |
| 1y Target Est | - |
| DCF Unlevered | TMBR DCF -> | |
|---|---|---|
| DCF Levered | TMBR LDCF -> | |
| ROE | -520.78% | Strong Sell |
| ROA | -452.39% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | -20.80% | Neutral |
| P/E | -0.17 | Neutral |
| P/B | -0.40 | Neutral |
Latest TMBR news
About
Download (Excel)Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-002, a proprietary topical formulation of rapamycin, which is in Phase 2b clinical trial for the treatment of facial angiofibroma in tuberous sclerosis complex, a multisystem genetic disorder resulting in the growth of hamartomas in multiple organs. It is also involved in the development of TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. In addition, the company engages in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. It has license agreement with AFT Pharmaceuticals Limited. The company was founded in 2019 and is headquartered in Basking Ridge, New Jersey.